Renub Research has recently published a report titled "Cancer Pain Management Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" providing a detailed industry analysis that includes market share insights. In addition, the report covers research on competitors and regions and current advancements in the cancer pain management market. The cancer pain management industry shall experience a CAGR of nearly 5.31% from 2022 to 2030.

Various factors, including tumour compression, nerve damage, inflammation, metastasis, and psychological factors, can cause cancer-related pain. In addition, cancer treatments like chemotherapy, radiation therapy, and surgery can cause pain. Treatment options for cancer pain include pain relievers, drugs, radiation therapy, chemotherapy, surgery, nerve blocks, palliative care, and complementary therapies. The most effective pain management plan typically involves a combination of these treatments tailored to the patient's needs.
The cancer pain management market shall grow due to several factors, such as the rising global incidence of cancer, increasing demand for efficient pain relief treatments, growing utilization of opioids for pain management, and the emergence of novel drugs and therapies. As per the National Centre for Health Statistics, the United States shall witness 1,958,310 new cancer cases and 609,820 cancer-related deaths in 2023. Additionally, the aging population is another factor driving the growth of the cancer pain management market, as cancer is more common in older individuals who may require advanced pain management approaches.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=cancer-pain-management-market-p.php

Advancements in technology and research are also driving the growth of the cancer pain management market. New drug formulations, delivery methods, and treatment modalities are being developed to manage cancer pain better. In addition, the increasing availability of palliative care services and the growing adoption of complementary therapies like acupuncture and massage also contribute to the growth of the cancer pain management market. Moreover, governments and healthcare organizations are also focusing on improving cancer pain management by increasing awareness, providing better training to healthcare professionals, and investing in research and development.

Targeted therapies are in demand in the cancer pain management market for their effectiveness in managing pain associated with specific cancer types and reducing side effects
Targeted therapies in the cancer pain management market include drugs that target specific proteins or molecules involved in the surge and spread of cancer cells or treatments that use antibodies or substances to vitalize the immune system to attack cancer cells. They are used to manage pain associated with specific types of cancer, often in combination with other treatments like chemotherapy or radiation therapy. Additionally, advances in biotechnology and genomics have allowed for the development of more effective targeted therapies tailored to the unique characteristics of each patient's cancer. Finally, targeted therapies may offer a better long-term prognosis for patients, potentially reducing the need for ongoing pain management interventions.

Dominance of opioids in the cancer pain management market is due to their availability in different forms and their ability for usage in combination with other treatments
The effectiveness of opioids in managing pain, including cancer pain, is due to their ability to secure opioid receptors in the brain and spinal cord, reducing pain perception. In addition to their effectiveness, opioids are available in various forms, such as tablets, injections, and patches, providing flexibility in treatment. Their affordability and extensive use in pain management over the years have also contributed to their dominance in the cancer pain management market. Finally, opioids can be combined with other treatments like chemotherapy and radiation therapy for a more comprehensive approach to cancer pain management.
Breast cancer segment in the cancer pain management market shall register a high growth rate in the future
As breast cancer is one of the most common cancers affecting women, it contributes to the growth of the cancer pain management market. Breast cancer is the most recurring cancer among adults, with over 2.3 million cases occurring annually globally, as the World Health Organization (WHO) predicted. In addition, breast cancer is the first or second leading cause of female cancer deaths in 95% of countries.
Moreover, the increasing prevalence of breast cancer globally and the increasing awareness about the significance of early observation and treatment of breast cancer are also driving the growth of the cancer pain management market. Furthermore, developing new and effective pain management therapies specifically for breast cancer is fuelling the development of the cancer pain management market.

United States has hegemony in the Cancer Pain Management Market

The supremacy of the US in the cancer pain management market is due to various factors, such as well-established healthcare infrastructure, high healthcare spending, favourable reimbursement policies, many cancer patients, and a growing aging population. Additionally, the US is home to major players in the pharmaceutical industry and significant investments in research and development activities, which have contributed to the development of advanced cancer pain management therapies. The US also has a robust regulatory framework, which ensures the safety and efficacy of cancer pain management drugs and medicines.

Competitive Landscape

Some notable players in the cancer pain management industry include Daiichi Sankyo Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Limited, Sanofi, Johnson & Johnson, and Eli Lilly.

Market Summary:

Treatment - The Report covers the Cancer Pain Management Market by treatment from 7 viewpoints

• Immunotherapy
• Radiotherapy
• Chemotherapy
• Hormone Therapy
• Targeted Therapies
• Inhibitors
• Surgery
• Others

Drug Type – The Cancer Pain Management Market, by drug type, break up into 3 viewpoints

• (Opioids,
• Non-Opioids
• Nerve Blockers

Disease Indication - By disease indication, the Cancer Pain Management Market is broken up into 6 viewpoints

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Regions - By regions, the Cancer Pain Management Market breaks up into10 viewpoints

• United States
• United Kingdom
• Japan
• France
• Germany
• Italy
• Spain
• Saudi Arabia
• China
• Korea

Key Players- All the major players of the Global Folding Furniture Market have been covered from 3 Viewpoints (Overview, Recent Developments, and Sales Analysis)

• Daiichi Sankyo Co., Ltd.
• Hisamitsu Pharmaceutical Co., Inc.
• Orexo AB
• Pfizer Inc
• Teva Pharmaceutical Industries Limited
• Sanofi
• Johnson & Johnson
• and Eli Lilly

Browse Related Report:

Coronary Artery Disease Market: https://www.renub.com/coronary-artery-disease-market-p.php
Alzheimer's Drugs Market: https://www.renub.com/alzheimer-s-pipeline-drugs-review-alzheimer-s-disease-drug-market-and-forecast-global-analysis-131-p.php

Chronic Obstructive Pulmonary Disease Market: https://www.renub.com/chronic-obstructive-pulmonary-disease-market-p.php

Age-Related Macular Degeneration Market: https://www.renub.com/age-related-macular-degeneration-market-p.php

Diabetes Drug Market: https://www.renub.com/diabetes-drug-market-p.php

About the Company:

Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

Contact Us:

Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: [email protected]
LinkedIn: https://in.linkedin.com/company/renub-research
Web: www.renub.com